AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients
The CONVERGE IDE trial is a landmark prospective, randomized trial
underway in
“The full enrollment of the CONVERGE clinical trial is a significant
milestone for AtriCure,” said
The CONVERGE study’s primary efficacy endpoint is for enrolled patients
to be Afib, atrial tachycardia, and atrial flutter free, absent class I
and III AADs except for a previously failed or intolerant class I or III
anti-arrhythmic drugs, with no increase in dosage following the 3-month
blanking period through the 12 months’ post procedure follow-up visit.
The last patient follow-up is expected to be sometime in the third
quarter of 2019, after which the company will submit final documentation
to the
“The CONVERGE trial is an important step forward for the cardiology
community in furthering available treatment options for Afib patients,”
said Dr.
More information regarding the trial, including inclusion and exclusion criteria and primary and secondary outcome measures, can be found here: https://www.clinicaltrials.gov/ct2/show/NCT01984346
About
Forward-Looking Statements
This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/fls as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. We do not undertake to update our forward-looking statements. This document also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180828005187/en/
Source:
AtriCure, Inc.
Media Relations:
Valerie Storch-Willhaus,
612-605-3311
Senior Director, Corporate Marketing and Communications
vstorch-willhaus@AtriCure.com
or
Investor
Relations:
Andy Wade, 513-755-4564
Senior Vice President and
Chief Financial Officer
awade@AtriCure.com